Personalis, Inc. Operating Income
Personalis, Inc. (PSNL) reported Operating Income of -$33.59 million for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-04.
Financial Statements › Income Statement
us-gaap:OperatingIncomeLoss · last filed 2026-08-04
- Personalis, Inc. operating income (loss) for the quarter ending 2026-06-30 was -$33.59M.
- Personalis, Inc. operating income (loss) for the quarter ending 2026-03-31 was -$32.16M.
- Personalis, Inc. operating income (loss) for the quarter ending 2025-12-31 was -$25.27M.
- Personalis, Inc. operating income (loss) for the quarter ending 2025-09-30 was -$23.29M.
- Personalis, Inc. operating income (loss) for fiscal 2025 was -$88.06M.
- Personalis, Inc. operating income (loss) for fiscal 2024 was -$68.27M.
- Personalis, Inc. operating income (loss) for fiscal 2023 was -$109.94M.
- Personalis, Inc. operating income (loss) for fiscal 2022 was -$115.53M.
| Period end | Operating Income (Loss) 3 month | Operating Income (Loss) 6 month | Operating Income (Loss) 9 month | Operating Income (Loss) 12 month |
|---|---|---|---|---|
| 2026-06-30 | -$33.59M 10-Q · filed 2026-08-04 | -$65.75M 10-Q · filed 2026-08-04 | -$91.02M derived: sum of 3 quarters · filed 2026-08-04 | -$114.31M derived: sum of 4 quarters · filed 2026-08-04 |
| 2026-03-31 | -$32.16M 10-Q · filed 2026-05-07 | -$57.43M derived: sum of 2 quarters · filed 2026-05-07 | -$80.72M derived: sum of 3 quarters · filed 2026-05-07 | -$102.52M derived: sum of 4 quarters · filed 2026-08-04 |
| 2025-12-31 | -$25.27M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-26 | -$48.56M derived: sum of 2 quarters · filed 2026-02-26 | -$70.36M derived: sum of 3 quarters · filed 2026-08-04 | -$88.06M 10-K · filed 2026-02-26 |
| 2025-09-30 | -$23.29M 10-Q · filed 2025-11-04 | -$45.09M derived: sum of 2 quarters · filed 2026-08-04 | -$62.79M 10-Q · filed 2025-11-04 | -$80.90M derived: sum of 4 quarters · filed 2026-08-04 |
| 2025-06-30 | -$21.80M 10-Q · filed 2026-08-04 | -$39.50M 10-Q · filed 2026-08-04 | -$57.61M derived: sum of 3 quarters · filed 2026-08-04 | -$71.99M derived: sum of 4 quarters · filed 2026-08-04 |
| 2025-03-31 | -$17.70M 10-Q · filed 2026-05-07 | -$35.81M derived: sum of 2 quarters · filed 2026-05-07 | -$50.19M derived: sum of 3 quarters · filed 2026-05-07 | -$67.08M derived: sum of 4 quarters · filed 2026-05-07 |
| 2024-12-31 | -$18.11M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-26 | -$32.49M derived: sum of 2 quarters · filed 2026-02-26 | -$49.39M derived: sum of 3 quarters · filed 2026-02-26 | -$68.27M 10-K · filed 2026-02-26 |
| 2024-09-30 | -$14.38M 10-Q · filed 2025-11-04 | -$31.27M derived: sum of 2 quarters · filed 2025-11-04 | -$50.16M 10-Q · filed 2025-11-04 | -$74.13M derived: sum of 4 quarters · filed 2025-11-04 |
| 2024-06-30 | -$16.89M 10-Q · filed 2025-08-05 | -$35.77M 10-Q · filed 2025-08-05 | -$59.74M derived: sum of 3 quarters · filed 2025-08-05 | -$90.54M derived: sum of 4 quarters · filed 2025-08-05 |
| 2024-03-31 | -$18.88M 10-Q · filed 2025-05-06 | -$42.85M derived: sum of 2 quarters · filed 2025-05-06 | -$73.64M derived: sum of 3 quarters · filed 2025-05-06 | -$98.99M derived: sum of 4 quarters · filed 2025-05-06 |
| 2023-12-31 | -$23.97M derived: 10-K 12 month − 10-Q 9 month · filed 2025-02-27 | -$54.77M derived: sum of 2 quarters · filed 2025-02-27 | -$80.11M derived: sum of 3 quarters · filed 2025-02-27 | -$109.94M 10-K · filed 2025-02-27 |
| 2023-09-30 | -$30.79M 10-Q · filed 2024-11-06 | -$56.14M derived: sum of 2 quarters · filed 2024-11-06 | -$85.96M 10-Q · filed 2024-11-06 | -$118.05M derived: sum of 4 quarters · filed 2024-11-06 |
| 2023-06-30 | -$25.35M 10-Q · filed 2024-08-07 | -$55.17M 10-Q · filed 2024-08-07 | -$87.26M derived: sum of 3 quarters · filed 2024-08-07 | -$114.52M derived: sum of 4 quarters · filed 2024-08-07 |
| 2023-03-31 | -$29.82M 10-Q · filed 2024-05-08 | -$61.91M derived: sum of 2 quarters · filed 2024-05-08 | -$89.17M derived: sum of 3 quarters · filed 2024-05-08 | -$117.05M derived: sum of 4 quarters · filed 2024-05-08 |
| 2022-12-31 | -$32.09M derived: 10-K 12 month − 10-Q 9 month · filed 2024-02-28 | -$59.34M derived: sum of 2 quarters · filed 2024-02-28 | -$87.22M derived: sum of 3 quarters · filed 2024-02-28 | -$115.53M 10-K · filed 2024-02-28 |
| 2022-09-30 | -$27.26M 10-Q · filed 2023-11-07 | -$55.14M derived: sum of 2 quarters · filed 2023-11-07 | -$83.45M 10-Q · filed 2023-11-07 | -$103.67M derived: sum of 4 quarters · filed 2024-02-28 |
| 2022-06-30 | -$27.88M 10-Q · filed 2023-08-08 | -$56.19M 10-Q · filed 2023-08-08 | -$76.41M derived: sum of 3 quarters · filed 2024-02-28 | -$94.10M derived: sum of 4 quarters · filed 2024-02-28 |
| 2022-03-31 | -$28.31M 10-Q · filed 2023-05-03 | -$48.53M derived: sum of 2 quarters · filed 2024-02-28 | -$66.22M derived: sum of 3 quarters · filed 2024-02-28 | -$81.17M derived: sum of 4 quarters · filed 2024-02-28 |
| 2021-12-31 | -$20.23M derived: 10-K 12 month − 10-Q 9 month · filed 2024-02-28 | -$37.92M derived: sum of 2 quarters · filed 2024-02-28 | -$52.86M derived: sum of 3 quarters · filed 2024-02-28 | -$65.35M 10-K · filed 2024-02-28 |
| 2021-09-30 | -$17.69M 10-Q · filed 2022-11-02 | -$32.64M derived: sum of 2 quarters · filed 2022-11-02 | -$45.13M 10-Q · filed 2022-11-02 | -$58.50M derived: sum of 4 quarters · filed 2023-02-23 |
| 2021-06-30 | -$14.95M 10-Q · filed 2022-08-03 | -$27.44M 10-Q · filed 2022-08-03 | -$40.81M derived: sum of 3 quarters · filed 2023-02-23 | -$50.46M derived: sum of 4 quarters · filed 2023-02-23 |
| 2021-03-31 | -$12.49M 10-Q · filed 2022-05-04 | -$25.86M derived: sum of 2 quarters · filed 2023-02-23 | -$35.51M derived: sum of 3 quarters · filed 2023-02-23 | -$45.01M derived: sum of 4 quarters · filed 2023-02-23 |
| 2020-12-31 | -$13.37M derived: 10-K 12 month − 10-Q 9 month · filed 2023-02-23 | -$23.02M derived: sum of 2 quarters · filed 2023-02-23 | -$32.52M derived: sum of 3 quarters · filed 2023-02-23 | -$42.15M 10-K · filed 2023-02-23 |
| 2020-09-30 | -$9.65M 10-Q · filed 2021-11-04 | -$19.15M derived: sum of 2 quarters · filed 2021-11-04 | -$28.78M 10-Q · filed 2021-11-04 | -$35.97M derived: sum of 4 quarters · filed 2022-02-24 |
| 2020-06-30 | -$9.50M 10-Q · filed 2021-08-04 | -$19.12M 10-Q · filed 2021-08-04 | -$26.32M derived: sum of 3 quarters · filed 2022-02-24 | -$32.05M derived: sum of 4 quarters · filed 2022-02-24 |
| 2020-03-31 | -$9.63M 10-Q · filed 2021-05-05 | -$16.82M derived: sum of 2 quarters · filed 2022-02-24 | -$22.55M derived: sum of 3 quarters · filed 2022-02-24 | -$26.61M derived: sum of 4 quarters · filed 2022-02-24 |
| 2019-12-31 | -$7.20M derived: 10-K 12 month − 10-Q 9 month · filed 2022-02-24 | -$12.93M derived: sum of 2 quarters · filed 2022-02-24 | -$16.99M derived: sum of 3 quarters · filed 2022-02-24 | -$22.42M 10-K · filed 2022-02-24 |
| 2019-09-30 | -$5.73M 10-Q · filed 2020-11-05 | -$9.79M derived: sum of 2 quarters · filed 2020-11-05 | -$15.22M 10-Q · filed 2020-11-05 | -$18.37M derived: sum of 4 quarters · filed 2021-02-25 |
| 2019-06-30 | -$4.06M 10-Q · filed 2020-08-06 | -$9.49M 10-Q · filed 2020-08-06 | -$12.64M derived: sum of 3 quarters · filed 2021-02-25 | -$14.39M derived: sum of 4 quarters · filed 2021-02-25 |
| 2019-03-31 | -$5.43M 10-Q · filed 2020-05-07 | -$8.58M derived: sum of 2 quarters · filed 2021-02-25 | -$10.33M derived: sum of 3 quarters · filed 2021-02-25 | -$14.04M derived: sum of 4 quarters · filed 2021-02-25 |
| 2018-12-31 | -$3.15M derived: 10-K 12 month − 10-Q 9 month · filed 2021-02-25 | -$4.90M derived: sum of 2 quarters · filed 2021-02-25 | -$8.61M derived: sum of 3 quarters · filed 2021-02-25 | -$13.77M 10-K · filed 2021-02-25 |
| 2018-09-30 | -$1.75M 10-Q · filed 2019-11-13 | -$5.46M derived: sum of 2 quarters · filed 2019-11-13 | -$10.62M 10-Q · filed 2019-11-13 | |
| 2018-06-30 | -$3.71M 10-Q · filed 2019-08-13 | -$8.87M 10-Q · filed 2019-08-13 | ||
| 2017-12-31 | -$22.16M 10-K · filed 2020-03-25 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Fortrea Holdings Inc. (FTRE) | United States | $1.903B | -19.43 |
| CASTLE BIOSCIENCES INC (CSTL) | United States | $1.074B | -37.45 |
| Lumexa Imaging Holdings, Inc. (LMRI) | United States | $0.951B | |
| Fulgent Genetics, Inc. (FLGT) | United States | $0.593B | -6.70 |
| CareDx, Inc. (CDNA) | United States | $3.174B | 13.21 |
| BIODESIX INC (BDSX) | United States | $0.312B | |
| EXAGEN INC. (XGN) | United States | $0.212B | -5.95 |
| Freenome, Inc. (FRNM) | United States | $0.143B | |
| SERA PROGNOSTICS, INC. (SERA) | United States | $0.062B | -5.75 |
| AMERICAN SHARED HOSPITAL SERVICES (AMS) | United States | $0.010B | -5.64 |